8-K: SEED Therapeutics Secures $30M, IND Cleared for ST-01156

SEED Therapeutics, a clinical-stage biotechnology company, announced the completion of its $30 million Series A-3 financing and FDA clearance for its lead program, ST-01156, targeting RBM39.

Summary

• SEED Therapeutics completed a $30 million Series A-3 financing, comprising a $24 million first close in August 2024 and a $6 million second close in August 2025.
• The U.S. Food and Drug Administration (FDA) cleared SEED's Investigational New Drug (IND) application for its lead program, ST-01156, which targets RBM39.
• SEED anticipates entering first-in-human clinical trials for ST-01156 in Q1 2026.
• BeyondSpring Inc. (BYSI) and its majority-owned indirect subsidiary, SEED Technology Limited, are expected to collectively own approximately 38.03% of SEED's outstanding equity interest on an as-converted basis after the second close.
• BeyondSpring expects to continue consolidating SEED into its financial statements due to maintaining substantive control.
• SEED has received close to $60 million in combined equity, collaboration upfront, and milestone payments from partnerships with Eli Lilly and Eisai.
• ST-01156 is a brain-penetrant RBM39 degrader intended for Ewing sarcoma and other RBM39-dependent cancers.
• SEED's proprietary RITE3 platform has generated a pipeline of nine programs spanning oncology, neurodegeneration, immunology, and virology.

Sentiment

Score: 8

Explanation: The filing reports significant positive developments including successful financing, FDA IND clearance, and strong partner validation, marking a crucial transition to a clinical-stage company. These milestones significantly de-risk the company's lead program and provide substantial capital for future operations, indicating a very positive outlook despite inherent risks in drug development.

Positives

• Successful completion of a $30 million Series A-3 financing, providing capital for clinical advancement and pipeline expansion.
• FDA clearance of the IND application for ST-01156, marking SEED's transition into a clinical-stage company.
• Strong partner validation evidenced by nearly $60 million in combined equity, upfront, and milestone payments from Eli Lilly and Eisai.
• Lead candidate ST-01156 is a first-in-class rationally designed molecular glue degrader targeting RBM39, a historically undruggable disease driver.
• BeyondSpring maintains substantive control over SEED, allowing for consolidation of financial statements and potential value capture.
• SEED's RITE3 platform has generated a broad pipeline of nine programs across multiple therapeutic areas.

Risks

• Difficulties raising the anticipated amount needed to finance future operations for BeyondSpring and SEED on acceptable terms, if at all.
• Unexpected results of clinical trials.
• Delays or denial in the regulatory approval process.
• Results that do not meet expectations regarding the potential safety, ultimate efficacy, or clinical utility of product candidates.
• Increased competition in the market.

Future Outlook

SEED Therapeutics anticipates entering first-in-human clinical trials for its lead candidate, ST-01156, in Q1 2026. BeyondSpring expects to continue consolidating SEED into its financial statements.

Management Comments

• "FDA clearance of our IND is a defining milestone for SEED, marking our transition into a clinical-stage company. ST-01156 represents the first of a new generation of rationally designed molecular glue degraders. We continue to translate innovation into meaningful therapies for patients." Lan Huang, Ph.D., SEED Co-Founder, Chairman, and Chief Executive Officer.
• "Our equity financing, together with collaboration payments from Eli Lilly and Eisai, supplement our resources to move confidently into the clinic and to continue building a broad pipeline. We have the partners, capital, and momentum to deliver on SEEDs strategy." Bill Desmarais, SEED Chief Financial Officer and Chief Business Officer.

Industry Context

The successful IND clearance and financing for ST-01156 position SEED Therapeutics as a new entrant in the clinical-stage biotechnology sector, specifically in the emerging field of targeted protein degradation (TPD 2.0) and molecular glue degraders. This area is gaining significant interest for its potential to address historically undruggable disease drivers, with major pharmaceutical companies like Eli Lilly and Eisai investing in the space, indicating strong industry validation and a competitive landscape.

Comparison to Industry Standards

• The successful IND clearance for ST-01156 aligns with industry benchmarks for advancing novel drug candidates from preclinical to clinical stages, particularly for innovative mechanisms like molecular glue degraders.
• The $30 million Series A-3 financing, combined with nearly $60 million from partnerships with Eli Lilly and Eisai, demonstrates significant investor and strategic partner confidence, comparable to successful early-stage funding rounds for other promising biotech companies in the TPD space.
• SEED's RITE3 platform and pipeline of nine programs across multiple therapeutic areas (oncology, neurodegeneration, immunology, virology) suggest a broad strategic approach, similar to diversified biotech firms aiming to maximize platform utility.

Related Party Transactions

• BeyondSpring Inc. (the Company) and SEED Technology Limited (a majority-owned indirect subsidiary of the Company) are expected to own approximately 38.03% of SEED's outstanding equity interest.
• BeyondSpring expects to continue consolidating SEED into its financial statements.

Stakeholder Impact

• Shareholders (BeyondSpring): Increased value potential due to SEED's advancement to clinical stage and successful financing, strengthening BeyondSpring's consolidated financial position.
• Investors (SEED): Positive impact from successful Series A-3 financing and IND clearance, validating their investment.
• Patients: Potential for new, meaningful therapies, particularly for historically undruggable diseases like Ewing sarcoma, with ST-01156 entering clinical trials.
• Employees (SEED): Enhanced job security and growth opportunities as the company transitions to clinical stage and expands its pipeline.
• Partners (Eli Lilly, Eisai): Validation of their strategic investments and collaborations with SEED.

Next Steps

• Initiate first-in-human clinical trials for ST-01156 in Q1 2026.
• Continue building a broad pipeline of molecular glue degraders.

Key Dates

Recommendation

The successful completion of a $30 million Series A-3 financing, coupled with FDA IND clearance for its lead candidate ST-01156, represents a transformative milestone for SEED Therapeutics, and by extension, for BeyondSpring Inc. (BYSI) which maintains substantive control. The transition to a clinical-stage company significantly de-risks the lead program and opens the door for substantial value creation. Furthermore, the nearly $60 million in combined equity and collaboration payments from industry giants Eli Lilly and Eisai provide strong external validation of SEED's scientific platform and pipeline potential. These developments indicate robust progress, strong financial backing, and a clear path to clinical advancement in a high-potential therapeutic area (molecular glue degraders), making it a compelling investment opportunity.

Keywords

Biotechnology, Molecular Glue Degraders, Clinical Trials, FDA Clearance, IND Application, Series A-3 Financing, RBM39, Oncology, Ewing Sarcoma, Targeted Protein Degradation, BeyondSpring, SEED Therapeutics, Drug Development, Biopharma